Bruce Goldfarb Quoted in The New York Times
To help influence the outcome of that bet, Mr. Ackman has lobbied members of Congress and regulators to investigate the company, a move that has helped to push down the value of the stock.
“What’s unusual is that we’re talking about investors who are outsiders — the outsiders are potentially becoming insiders here by teaming up with Valeant,” said Bruce H. Goldfarb, president of Okapi Partners, a proxy solicitor.
For Valeant, already among the most acquisitive health care companies today, a deal for Allergan would be its largest yet.
Unusual Hostile Bid for Maker of Botox [New York Times]